What makes us different?

Our Darwin AI Peptide Discovery Platform

The increasing prevalence of chronic diseases is driving demand for innovative peptide therapeutics. NuvoBio is a peptide therapeutics company generating a pipeline of best-in class therapies, fueled by its innovative and highly differentiated drug discovery platform, DarwinAI.

Increased Accuracy

Leverage advanced computational modelling and high-throughput experimental validation, to enhance peptide specificity.

Accelerated Discovery

Harness cutting-edge AI-driven peptide design to rapidly identify and develop novel therapeutics, reducing research timelines and expediting breakthroughs

Disease Agnostic

Develop peptides with applications across therapeutics, diagnostics, and drug delivery, unlocking new possibilities in biotech and medicine.

NuvoBio Aims To Revolutionize Peptide Drug Discovery

NuvoBio’s revolutionary approach to peptide discovery accelerates drug development, while simultaneously expanding both the breadth of druggable targets and significantly reducing off-target risks. NuvoBio has a pipeline of novel peptide therapeutics, with demonstrated proof of concept paving the way for safer, more effective treatments.

Our Vision

Pioneering the future of peptide therapeutics through AI-driven innovation.

Our Mission

Accelerate drug discovery with intelligent peptide design for selective targeting.

Our Process

Harnessing Darwin AI to create precise, high-affinity peptides for cutting-edge therapies.

About us

Meet The Team That makes it possible

Our talented team of research scientists and computer engineers!

get in touch

reach out to us to get a quote

Accelerate your work with our cutting edge peptide discovery platform.

Frequently Asked Questions

What therapeutic areas does NuvoBio focus on?

NuvoBio is dedicated to developing innovative peptide therapeutics for high-impact health challenges. leveraging AI-driven peptide design, our work primarily focuses on addressing therapeutic unmet need, where traditional small-molecule and biologic therapies face limitations.

How can DarwinAI be used for custom peptide development?

DarwinAI is NuvoBio’s proprietary AI-driven platform designed to rapidly generate, optimize, and validate therapeutic peptides. Unlike traditional trial-and-error methods, DarwinAI learns from experimental protein interaction data to evolve peptides with enhanced specificity and minimized off-target effects. This approach allows for the rapid customization of peptides for specific therapeutic targets, accelerating drug discovery and reducing development timelines.

Why not use AlphaFold to predict Peptide-Protein interactions?

While AlphaFold is a tool for predicting protein structures, it is not optimized for modeling dynamic, and functional, protein interactions. Proteins function through transient, flexible binding mechanisms that require high-resolution experimental validation. DarwinAI integrates high-quality biological interaction data with computational modeling to evolve peptides that not only bind effectively but also maintain functional activity within biological systems.

How does NuvoBio ensure the stability and efficacy of its peptides?

NuvoBio employs a rigorous development pipeline to ensure the stability and efficacy of its peptide therapeutics. We incorporate advanced peptide modifications, structural analyses, and in vitro/in vivo validation to optimize pharmacokinetics, resistance to degradation, and target specificity. Our iterative AI-driven design process refines peptide properties to enhance therapeutic potential while maintaining safety and scalability for clinical development.